1 / 3

The PROs Further Support Durvalumab Chemo in Becoming The New Standard of Care

Patient-reported outcomes for the Phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.<br><br>Read More- https://www.delveinsight.com/asco-conference/article/durvalumab-chemo-highlights?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

yashb
Télécharger la présentation

The PROs Further Support Durvalumab Chemo in Becoming The New Standard of Care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advanced Biliary Tract Cancer- Delveinsight The PROs Further Support Durvalumab + Chemo in Becoming the New Standard of Care in 1st Line Advanced Biliary Tract Cancer Durvalumab + Chemo Highlights: ASCO 2022 Patient-reported outcomes for the Durvalumab, Gemcitabine, and Cisplatin Phase III TOPAZ-1 Study in Advanced Biliary Tract Cancer Durvalumab Mechanism of Action: Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants The PD-L1 antagonist Durvalumab from AstraZeneca is presently accepted for the treatment of lung cancer. Based on the TOPAZ-1 Phase 3 trial, the medicine recently received priority evaluation in the US for patients with locally advanced or metastatic biliary tract cancer. Durvalumab was added, and there was no discernible difference in the Time to deterioration; instead, patients in the durvalumab + gemcitabine + cisplatin group compared to those in the placebo +

  2. Advanced Biliary Tract Cancer- Delveinsight gemcitabine + cisplatin group reported their symptoms or functional status using either C30 or BIL21, or their Global Health Status/QoL (hazard ratio= 0.87; p=0.279). Hence the addition of durvalumab to gemcitabine + cisplatin improved OS and was well tolerated with no difference in TTD of QoL for patients, supporting Durvalumab + GC as a new treatment option for patients with BTC. KOL Insights "TOPAZ-1 is the first phase 3 trial to demonstrate that combining immunotherapy to conventional chemotherapy can increase survival in [BTC], and significantly, does so without producing any new severe adverse effects [AEs]," according to the study. - Expert Advice Combination chemotherapy is currently the gold standard of treatment for incurable biliary tract cancer. This standard has not altered in more than ten years. In order to establish a new standard of treatment, TOPAZ-1 is the first phase 3 trial to show the value of immunotherapy for better [OS] when combined with chemotherapy. The use of immunotherapy in [BTC] has shown promising outcomes, giving patients further cause for optimism. - Expert Advice Conclusion The most recent TOPAZ-1 study data represent a significant step forward for patients, clearly demonstrating a survival advantage for durvalumab coupled to chemotherapy over standard of care with an exceptional safety profile. In a situation where the prognosis is dire, this combination will offer a much-needed and perhaps game-changing new therapy option. Also, read- ASCO Conference 2020 | ASCO 2020 Abstracts | ASCO 2021 Highlights

  3. Advanced Biliary Tract Cancer- Delveinsight ASCO Medical Conference | ASCO 2021 | ASCO 2021 Conference | when in ASCO 2021 | 2021 ASCO | ASCO US | ASCO 2022 Annual Meeting | ASCO Abstract 2022 | ASCO 2021 Abstracts Latest Pharmaceutical Market Research Reports by DelveInsight Stem cell market | Medical marijuana market | Oncolytic virus cancer therapy pipeline | Small lymphocytic lymphoma market |CART pipeline | Bone metastasis in solid tumors market | Kawasaki disease market | Myopia treatment devices market | urology ultrasounds devices market |Technical due diligence firms | Lice infestations market | Hepatic cirrhosis market | SGLT2 Inhibitors market | Pediatric growth hormone deficiency PGHD Market | Anti- neutrophil cytoplasmic antibody-associated vasculitis market | Varicella zoster HHV 3 infections market | Radiation induced esophagitis market About Us DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

More Related